A common methylenetetrahydrofolate reductase gene mutation and longevity

Atherosclerosis

Volumn 141, Issue 2, 1998, Pages 315-319

  Brattström, Lars ^a   Zhang, Ying ^b   Hurtig, Mats ^a   Refsum, Helga ^b   Östensson, Staffan ^a   Fransson, Lars ^a   Jonés, Krister ^a   Landgren, Finn ^a   Brudin, Lars ^a   Ueland, Per M ^b  

^a KALMAR COUNTY HOSPITAL   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cardiovascular disease; Folate; Homocysteine; Longevity; Meta analysis; Methylenetetrahydrofolate reductase; Mutation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HOMOZYGOTE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METHYLATION; PREVALENCE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMANS; HYPERHOMOCYSTEINEMIA; INFANT, NEWBORN; LONGEVITY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUTATION; ODDS RATIO; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; RISK FACTORS; SWEDEN;

EID: 0032401552     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00154-3     Document Type: Article

References (19)

1. Ueland PM, Refsum H, Brattström L Plasma homocysteine and cardiovascular disease. Francis RB Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. 1992;183-235 Marcel Dekker, New York.
2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc. 274:1995;1049-1057.
3. Graham IM, Daly LE, Refsum H, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Lúis AC, Parrot-Roulaud FM, Soon Tan K, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AK, Andria G Plasma homocysteine as a risk factor for vascular disease. The European concerted action project. J Am Med Assoc. 277:1997;1775-1781.
4. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 337:1997;230-236.
5. Brattström L, Lindgren A, Israelsson B, Andersson A, Hultberg B Homocysteine and cysteine-determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 236:1994;633-641.
6. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH Vitamin status and intake as primary determinants of homocysteinemia in the elderly. J Am Med Assoc. 270:1994;2693-2698.
7. Brattström L Vitamins as homocysteine-lowering agents. J Nutr. 126:1996;1276S-1280.
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heizer M, Kluijtmans LAJ, van den Henvel LP, Rozen R A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nat Genet. 10:1995;111-113.
9. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentration. Circulation. 93:1996;7-9.
10. Harmon DL, Woodside JV, Yarnell JWG, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS, Evans A The 'thermolabile' variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med. 89:1996;571-577.
11. Ma J, Stampfer MJ, Nennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willet WC, Rozen R Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
12. Ulvik A, Refsum H, Kluijtmans LAJ, Ueland P The C677T mutation of the methylenetetrahydrofolate reductase gene determined in human blood or plasma by a method involving multiinjection capillary electrophoresis and laser-induced fluorescence detection. Clin Chem. 43:1997;267-272.
13. Faure-Delanef L, Quéré I, Chassé JF, Guerassimenko O, Lesaulnier M, Bellet H, Zittoun J, Kamoun P, Cohen D Methylenetetrahydrofolate reductase thermolabile variant and human longevity. Am J Hum Genet. 60:1997;1001-1002.
14. Galinsky D, Tysoe C, Brayne CE, Easton DG, Huppert FA, Dening TR, Paykel ES, Rubinsztein DC Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Atherosclerosis. 129:1997;177-183.
15. Harmon DL, McMaster D, Shields DC, Whitehead AS, Rea IM MTHFR thermolabile genotype frequencies and longevity in Northern Ireland. Atherosclerosis. 131:1997;137-138.
16. Rees DC, Liu YT, Cox MJ, Elliot P, Wainscoat JS Factor V Leiden and thermolabile methylenetetrahydrofolate reductase in extreme old age. Thromb Haemost. 78:1997;1357-1359.
17. Sandercock P The odds ratio: a useful tool in neuroscience. J Neurol Neurosurg Psychiatry. 52:1989;817-820.
18. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 μmol/l). The Hordaland homocysteine study. J Clin Invest. 98:1996;2174-2183.
19. Brattström L, Wilcken DEL, Öjrvol J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but to vascular disease - the result of a meta-analysis. Circulations (in press).